European Commission approves Lonsurf in combination with bevacizumab for the third-line treatment of metastatic colorectal cancer – Servier + Taiho

Taiho Pharmaceutical announced that its partner Servier, has won European regulatory approval for Lonsurf (trifluridine + tipiracil) in combination with bevacizumab for the third-line treatment of metastatic colorectal cancer (mCRC). The European Commission gave its approval to the combination therapy in adult patients with mCRC who have received two prior anticancer treatment regimens, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.

The clearance is based on data from a global PIII study called SUNLIGHT, which gauged Lonsurf plus bevacizumab against Lonsurf alone in patients with refractory mCRC following two chemotherapy regimens.